Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials

  • Authors:
    • Mengling Song
    • Chunlian Liu
    • Rong Hu
    • Feimiao Wang
    • Zhenghao Huo
  • View Affiliations

  • Published online on: November 27, 2019     https://doi.org/10.3892/etm.2019.8251
  • Pages: 786-796
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present meta‑analysis was to evaluate the effects of the addition of single‑dose gonadotropin‑releasing hormone agonist (GnRHa) for luteal support on pregnancy outcomes in females partaking in in vitro fertilization or intracytoplasmic sperm injection cycles. In total, the studies were hand‑searched from six electronic databases to compare the pregnancy outcomes between single‑dose GnRHa administered as luteal phase support (GnRHa group) and regular luteal support (control group). In the GnRHa group, single‑dose GnRH agonist were administered at 5/6 days after IVF/ICSI procedures. In the control group, single‑dose GnRH agonist was not added during luteal phase support. Only randomized controlled trials were included. Sensitivity analysis was performed using Revman 5.3 software; the high heterogeneity identified in the present analysis was primarily caused by one study included. Following exclusion of this particular study, the meta‑analysis results indicated significantly higher rates of ongoing pregnancy or live birth per transfer (P=0.002), clinical pregnancy per transfer (CPR; P=0.001) and multiple pregnancy per pregnancy (P=0.020) in the GnRHa group compared with those in the control group. Meta‑analysis of a subgroup of trials with long‑acting GnRH‑a ovarian treatment protocols indicated that the rate of ongoing pregnancy or live birth (P=0.080), CPR (P=0.090) and multiple pregnancy per pregnancy (P=0.140) were not significantly different between the two groups. However, the results from trials that had used a multi‑dose GnRH antagonist ovarian treatment protocol indicated a significantly higher ongoing pregnancy or live birth rate per transfer (P=0.010), CPR per transfer (P<0.0001) and multiple pregnancy rate per pregnancy (P=0.003) compared with those in the control group. The present results suggested that administration of single‑dose GnRH agonist in the luteal phase may be an ideal choice for patients undergoing IVF/ICSI therapy.
View Figures
View References

Related Articles

Journal Cover

January-2020
Volume 19 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Song M, Liu C, Hu R, Wang F and Huo Z: Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials. Exp Ther Med 19: 786-796, 2020.
APA
Song, M., Liu, C., Hu, R., Wang, F., & Huo, Z. (2020). Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 19, 786-796. https://doi.org/10.3892/etm.2019.8251
MLA
Song, M., Liu, C., Hu, R., Wang, F., Huo, Z."Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials". Experimental and Therapeutic Medicine 19.1 (2020): 786-796.
Chicago
Song, M., Liu, C., Hu, R., Wang, F., Huo, Z."Administration effects of single‑dose GnRH agonist for luteal support in females undertaking IVF/ICSI cycles: A meta‑analysis of randomized controlled trials". Experimental and Therapeutic Medicine 19, no. 1 (2020): 786-796. https://doi.org/10.3892/etm.2019.8251